权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Native Hemodynamic Measurement as Feedback Control for Mechanical Cardiac Support

天然血流动力学测量作为机械心脏支持的反馈控制

基本信息

批准号：
10482251
负责人：
John E Porterfield
金额：
$ 49.86万
依托单位：
BRIDGESOURCE MEDICAL CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-05-03 至 2024-06-14
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10482251
关键词：
Acute Acute myocardial infarction Age Agreement Animal Model Animals Blood Cardiac Cardiac Output Cardiac Volume Cardiogenic Shock Cardiomyopathies Catheterization Catheters Clinical Consultations Device Removal Devices Echocardiography Elderly Excision Experimental Designs Feedback Goals Grant Heart Heart Atrium Heart failure Hospitals Human Implant In Vitro Judgment Left ventricular structure Licensing Measurement Measures Medical Medical Device Methods Monitor Myocardial Infarction Noise Output Patients Phase Physicians Prevalence Principal Investigator Procedures Process Pump Recovery Research Personnel Risk Sepsis Signal Transduction Small Business Innovation Research Grant Speed Techniques Technology Testing Time Ventricular Weaning Work aortic valve ascending aorta base blood pump cardiac device cardiac implant case-by-case basis design design verification experience hemodynamics in vivo instrumentation manufacturability mechanical circulatory support mechanical load mortality older patient overtreatment pre-clinical pressure prototype treatment duration verification and validation

项目摘要

Abstract Temporary Mechanical Circulatory Support (MCS) devices have been an effective means of temporary support in patients for two indications: acute myocardial infarction (MI) with or without cardiogenic shock (CS), and acute decompensated heart failure (HF). These ailments strike the elderly the hardest and are simultaneously more prevalent as age progresses. Cardiogenic shock after MI is more common in elderly patients than in the young, and HF has increasing prevalence with age (60-79, 6% have HF, for over 80, 10% have HF). In these patients, a short- term MCS device is a catheter delivered pump that can be placed in the LV, and pump blood across the aortic valve, to help maintain forward flow while unloading the failing heart. The key metric for optimizing the use of these devices includes a combination of pressure, and volume measurement. While pressure is already commonly measured on-device, MCS devices on the market today cannot estimate the total Cardiac Output of the heart, a key component of Cardiac Power Output (CPO, CO x mean aortic pressure) which is now well accepted as the single most important correlate of mortality in cardiogenic shock. Optimization of ongoing treatment as well as when to wean the patient from the MCS device to transition them to recovery (or a more permanent device) currently lacks a real-time, accurate measure of CO (necessary to calculate CPO). We propose integrating a proven LV volume measurement (admittance-based technology) capable of determining CO directly onto the MCS device, allowing the device to actively change pump speed (and therefore effect CPO) to respond to changing patient condition. In this phase 2 effort, BridgeSource Medical will demonstrate how admittance-based technology can be redeveloped for application on existing MCS device platforms.

摘要